Detalles de la búsqueda
1.
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Mult Scler
; 23(13): 1736-1747, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28080250
2.
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
J Neurol Neurosurg Psychiatry
; 87(5): 468-75, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26111826
3.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
N Engl J Med
; 362(5): 402-15, 2010 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-20089954
4.
The effect of plasma exchange on serum anti-JC virus antibodies.
Mult Scler
; 19(7): 912-9, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23232602
5.
Lessons learned after 20 years of real-world experience with natalizumab.
Mult Scler Relat Disord
; 80: 105048, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37866023
6.
Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica.
J Clin Apher
; 27(4): 183-92, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22488449
7.
Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study.
Mult Scler J Exp Transl Clin
; 8(4): 20552173221135888, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36407472
8.
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis.
Mult Scler J Exp Transl Clin
; 6(2): 2055217320918619, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32440353
9.
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
JAMA Neurol
; 77(5): 582-592, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32065623
10.
Biochemical analysis of CTLA-4 immunoreactive material from human blood.
BMC Immunol
; 10: 51, 2009 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-19772653
11.
Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.
Mult Scler Relat Disord
; 31: 157-164, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31005729
12.
Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
J Comp Eff Res
; 8(5): 305-316, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30754997
13.
Proceedings of the Inaugural Strategy Meeting for the Establishment of a Southeast Asia Regional Therapeutic Plasma Exchange Consortium for Neurological Disorders.
Ther Apher Dial
; 23(3): 289-297, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30927331
14.
Vascular access for therapeutic plasma exchange.
Muscle Nerve
; 48(4): 624, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23575805
15.
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Mult Scler Relat Disord
; 26: 211-218, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30273841
16.
Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies.
Mult Scler Relat Disord
; 18: 60-64, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29141823
17.
Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.
Mult Scler Relat Disord
; 17: 107-115, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29055438
18.
Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study.
Curr Ther Res Clin Exp
; 67(1): 55-65, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24678083
19.
Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence.
Ther Adv Neurol Disord
; 9(2): 130-47, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27006700
20.
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.
Mult Scler Relat Disord
; 9: 36-46, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27645341